Jefferies Rates Five Indian CRDMO Stocks as 'Buy' with Noted Upside Potential
Jefferies has rated five Indian CRDMO stocks as 'Buy,' highlighting Sai Life Sciences and Divi's Laboratories as top picks, with Anthem Biosciences offering the highest potential upside. The brokerage's positive outlook follows a strong June quarter, with companies under its coverage reporting 19% year-on-year growth and beating earnings estimates. Gland Pharma was upgraded from 'Hold' to 'Buy' due to improved sales and margins. Order-book visibility remains strong, with Sai Life Sciences and Anthem Biosciences securing significant revenue coverage for FY27.
First-hand measurement across 2 sources
We measured how 2 outlets covered this story. No outlet gave this story a measurable political slant — there is no left–right reading to report. Overall sentiment is positive (75/100). Lens Score 35/100.
Outlets measured: thefinancialexpress, thefinancialexpress. See how each one headlined and framed the same story in the source comparison below.
AI Analysis
Sentiment was consistent across outlets (75–75/100), indicating broadly factual reporting rather than editorialising.
Coverage timeline
thefinancialexpress broke this story on 27 Aug, 05:08 am. Other outlets followed.